Aptar Pharma has provided the delivery system and regulatory support for Adapt Pharma’s Narcan, which is the first US FDA-approved nasally administered, needle-free, ready-to use medication that can stop or reverse the effects of an opioid overdose.
Narcan contains naloxone, an opioid antagonist; the product is marketed in the US for emergency treatment of opioid overdose.
'By making Narcan Nasal Spray available, we hope to increase everyone’s access to emergency treatments across the US,' said Seamus Mulligan, Chairman and CEO of Adapt Pharma.
Aptar Pharma has brought to the partnership its experience in nasal drug delivery and regulatory expertise to support Adapt Pharma’s new drug application.
'We have collaborated closely with Adapt Pharma to ensure the rapid approval of this potentially life-saving product using our Unit-dose System (UDS),' said Salim Haffar, President of Aptar Pharma.
'We are continually investing in resources and capabilities to support our customers in reaching the market quickly.'
Estimated at more than US$2bn in 2015, the world market for intra-nasal spray systemic drug delivery has experienced strong growth in the last few years. The list of therapies treated via the nasal route continues to grow from the traditional areas of migraine, osteoporosis and endometriosis, to include post-operative pain (ketorolac), cancer pain (fentanyl), osteoporosis, prostate cancer, urinary incontinence, anaemia and vaccinations.
Aptar Pharma’s single-shot UDS system’s primeless feature combined with 360° orientation offer the patient ready-to-use convenience.
